stockrowMadrigal Pharmaceuticals, Inc.
MDGL Healthcare Biotechnology
Madrigal Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $958.4 million, up 432.1% from fiscal 2024.
- Revenue
- +50.1%
- EPS
- +147.3%
- Free cash flow
- +53.5%
- Total debt
- +0.45%
Quarter to September 2026, against a year earlier
Follow MDGL
Alert me
Madrigal Pharmaceuticals, Inc. (MDGL) EPS (diluted)
Madrigal Pharmaceuticals, Inc.'s EPS (diluted) for fiscal 2025 was −$12.85, compared with −$21.90 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$5.98. Over the past ten years it has ranged from −$40.03 (fiscal 2015) to −$2.22 (fiscal 2018); the current reading is higher than 64% of that period. Madrigal Pharmaceuticals, Inc. ranks 461st of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$12.85 | — |
| FY2024 | −$21.90 | — |
| FY2023 | −$19.99 | — |
| FY2022 | −$17.23 | — |
| FY2021 | −$14.63 | — |
| FY2020 | −$13.09 | — |
| FY2019 | −$5.45 | — |
| FY2018 | −$2.22 | — |
| FY2017 | −$2.54 | — |
| FY2016 | −$5.07 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $1.83 | — |
| Jun 2026 | −$1.99 | — |
| Mar 2026 | −$3.25 | — |
| Dec 2025 | −$2.57 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $7.37 |
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| PTGX Protagonist Therapeutics, Inc. compare | $1.03 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| SYRE Spyre Therapeutics, Inc. compare | −$3.07 |
| MDGL Madrigal Pharmaceuticals, Inc. | −$5.98 |
| CYTK Cytokinetics, Incorporated compare | −$6.04 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on MDGL
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement